Related Experiment Video
Updated: Jan 27, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint
Jeroen de Filette1, Corina Emilia Andreescu1, Filip Cools2
1Department of Endocrinology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Abstract:
Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies. The incidence of endocrine adverse events provoked by these immune checkpoint inhibitors (ICI) is based on data from randomized controlled trials, which have their drawbacks. PubMed was searched through August 22nd, 2017, by 2 reviewers independently (J.d.F. and C.E.A.). Early phase I/II, phase III experimental trials, prospective and retrospective observational studies were included. The weighted incidence and risk ratio were estimated for hypophysitis, primary thyroid disease, primary adrenal insufficiency, and diabetes mellitus. Their management is discussed in a systematic review. A total of 101 studies involving 19 922 patients were included. Ipilimumab-treated patients experienced hypophysitis in 5.6% (95% CI, 3.9-8.1), which was higher than nivolumab (0.5%; 95% CI, 0.2-1.2) and pembrolizumab (1.1%; 95% CI, 0.5-2.6). PD-1/PD-L1 inhibitors had a higher incidence of thyroid dysfunction - particularly hypothyroidism (nivolumab, 8.0%; 95% CI, 6.4-9.8; pembrolizumab, 8.5%; 95% CI, 7.5-9.7; PD-L1, 5.5%; 95% CI, 4.4-6.8; ipilimumab, 3.8%; 95% CI, 2.6-5.5). Combination therapy was associated with a high incidence of hypothyroidism (10.2-16.4%), hyperthyroidism (9.4-10.4%), hypophysitis (8.8-10.5%), and primary adrenal insufficiency (5.2-7.6%). Diabetes mellitus and primary adrenal insufficiency were less frequent findings on monotherapy. Our meta-analysis shows a high incidence of endocrine adverse events provoked by single agent checkpoint blockade, further reinforced by combined treatment.
Insights
Immune checkpoint inhibitors (ICIs) like CTLA-4, PD-1, and PD-L1 can cause endocrine issues. This meta-analysis reveals a high incidence of these adverse events, especially with combination therapies.
Area of Science:
- Oncology
- Immunology
- Endocrinology
Background:
- Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, or PD-L1 are standard treatments for advanced cancers.
- The incidence of endocrine adverse events from ICIs is not fully characterized, particularly from real-world data.
- Randomized controlled trials have limitations in capturing the full spectrum of ICI-induced endocrine toxicities.
Purpose of the Study:
- To systematically review and meta-analyze the incidence of endocrine adverse events associated with immune checkpoint inhibitors.
- To compare the risk of endocrine toxicities among different ICI agents (ipilimumab, nivolumab, pembrolizumab) and combination therapies.
- To provide a comprehensive overview of ICI-induced hypophysitis, thyroid dysfunction, adrenal insufficiency, and diabetes mellitus.
Main Methods:
- A systematic literature search of PubMed was conducted up to August 22nd, 2017.
- Included studies comprised early phase I/II, phase III trials, and observational studies (prospective and retrospective).
- Weighted incidence and risk ratios for specific endocrine adverse events were estimated across 101 studies involving 19,922 patients.
Main Results:
- Hypophysitis incidence was higher with ipilimumab (5.6%) compared to nivolumab (0.5%) and pembrolizumab (1.1%).
- PD-1/PD-L1 inhibitors showed a higher incidence of hypothyroidism (8.0-8.5%) than ipilimumab (3.8%).
- Combination ICI therapy significantly increased the incidence of hypothyroidism (10.2-16.4%), hyperthyroidism (9.4-10.4%), hypophysitis (8.8-10.5%), and adrenal insufficiency (5.2-7.6%).
Conclusions:
- Single-agent checkpoint blockade therapy is associated with a substantial incidence of endocrine adverse events.
- Combination ICI therapy further elevates the risk and incidence of these endocrine toxicities.
- Awareness and monitoring for endocrine adverse events are crucial in patients receiving ICI therapy.
Related Concept Videos
Endocrine Signaling
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
What is the Endocrine System?
The Endocrine System
An Overview of the Endocrine System
The endocrine system collaborates...
Structures of the Endocrine System
